ICU Medical’s (ICUI) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of ICU Medical (NASDAQ:ICUIFree Report) in a research report sent to investors on Wednesday morning,Benzinga reports.

A number of other brokerages also recently weighed in on ICUI. Jefferies Financial Group initiated coverage on ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. Raymond James raised their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. KeyCorp boosted their target price on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Finally, StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and an average target price of $173.00.

Check Out Our Latest Analysis on ICU Medical

ICU Medical Stock Performance

NASDAQ ICUI opened at $167.86 on Wednesday. The firm’s 50 day simple moving average is $176.43 and its 200 day simple moving average is $142.99. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of -36.73 and a beta of 0.66. The company has a current ratio of 2.29, a quick ratio of 1.08 and a debt-to-equity ratio of 0.75. ICU Medical has a 1 year low of $82.82 and a 1 year high of $196.26.

Insider Activity

In related news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,973,261.12. This trade represents a 10.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,502 shares of company stock valued at $6,573,496. 6.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock valued at $99,687,000 after purchasing an additional 48,106 shares during the period. Barclays PLC increased its position in shares of ICU Medical by 15.6% during the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after buying an additional 8,010 shares during the period. XTX Topco Ltd bought a new position in ICU Medical during the third quarter worth $342,000. EP Wealth Advisors LLC acquired a new position in ICU Medical in the third quarter valued at $247,000. Finally, Jane Street Group LLC boosted its position in ICU Medical by 137.5% during the third quarter. Jane Street Group LLC now owns 28,729 shares of the medical instruments supplier’s stock valued at $5,235,000 after acquiring an additional 16,635 shares during the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Further Reading

Analyst Recommendations for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.